In Australia, a new project aims to bring industry and academia closer together

10 April 2017

A new project is being launched by Australian pharmaceutical companies, in collaboration with academic and research centers, to build ties between research and industry.

The Bridge Program, which commences in June, will provide 100 participants a mix of online and residential training and will provide a travel scholarship to visit overseas pharmaceutical research facilities and develop global experience and business networks.

The initiative is funded with A$1 million ($750,000) and is being launched by a number of pharmaceutical, venture capital firms and other organizations, including AbbVie (NYSE: ABBV), Boehringer Ingelheim, Celgene (Nasdaq: CELG) and Novartis (NOVN: VX).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK